Picture of hVIVO logo

HVO hVIVO News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapHigh Flyer

REG - hVIVO plc - Total Voting Rights





 




RNS Number : 2393W
hVIVO plc
09 December 2019
 

hVIVO plc

 

("hVIVO or the "Company")

 

Total Voting Rights

 

At 9 December 2019 the Company's capital consisted of 83,293,129 ordinary shares of 5 pence each in issue with International Securities Identification Number GB00B6ZM0X53. This figure (83,293,129) may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

For further information please contact:

 

hVIVO plc

+44 (0)20 7756 1300

Anesh Patel, Interim Finance Director and Company Secretary


Fleur Wood, EVP, Investor Relations & Communications




Numis Securities Limited (Nominated Adviser)

+44 (0)20 7260 1000

Freddie Barnfield / Huw Jeremy




FTI Consulting (Financial PR)

+44 (0)20 3727 100

Simon Conway / Victoria Foster Mitchell


 

Notes to Editors:

hVIVO plc is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRUGGRUPUPBGWB

Recent news on hVIVO

See all news